RVNC vs. HRTX, MRSN, GBIO, STTK, ARCT, DVAX, BLTE, LBPH, DAWN, and RCUS
Should you be buying Revance Therapeutics stock or one of its competitors? The main competitors of Revance Therapeutics include Heron Therapeutics (HRTX), Mersana Therapeutics (MRSN), Generation Bio (GBIO), Shattuck Labs (STTK), Arcturus Therapeutics (ARCT), Dynavax Technologies (DVAX), Belite Bio (BLTE), Longboard Pharmaceuticals (LBPH), Day One Biopharmaceuticals (DAWN), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical preparations" industry.
Heron Therapeutics (NASDAQ:HRTX) and Revance Therapeutics (NASDAQ:RVNC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.
Heron Therapeutics currently has a consensus target price of $6.00, indicating a potential upside of 96.72%. Revance Therapeutics has a consensus target price of $11.50, indicating a potential upside of 193.37%. Given Heron Therapeutics' higher probable upside, analysts clearly believe Revance Therapeutics is more favorable than Heron Therapeutics.
Heron Therapeutics has higher earnings, but lower revenue than Revance Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.
Heron Therapeutics received 260 more outperform votes than Revance Therapeutics when rated by MarketBeat users. Likewise, 69.05% of users gave Heron Therapeutics an outperform vote while only 63.88% of users gave Revance Therapeutics an outperform vote.
80.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 97.7% of Revance Therapeutics shares are held by institutional investors. 6.4% of Heron Therapeutics shares are held by insiders. Comparatively, 5.1% of Revance Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Heron Therapeutics has a net margin of -61.28% compared to Heron Therapeutics' net margin of -134.10%.
Heron Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.
In the previous week, Heron Therapeutics had 3 more articles in the media than Revance Therapeutics. MarketBeat recorded 4 mentions for Heron Therapeutics and 1 mentions for Revance Therapeutics. Heron Therapeutics' average media sentiment score of 1.25 beat Revance Therapeutics' score of 0.23 indicating that Revance Therapeutics is being referred to more favorably in the news media.
Summary
Heron Therapeutics beats Revance Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Revance Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RVNC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Revance Therapeutics Competitors List
Related Companies and Tools
